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A B S T R A C T
Background
Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during exercise and is relieved
with rest. Buflomedil is a vasoactive agent used to treat peripheral vascular disease. However, its clinical efficacy for IC has not yet been
critically examined. This is an update of a Cochrane review first published in 2000, and previously updated in 2007 and 2008.
Objectives
To evaluate the available evidence on the efficacy of buflomedil for IC.
Search methods
For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last
searched January 2013) and CENTRAL (2012, Issue 12).
Selection criteria
Double-blinded, randomized controlled trials (RCTs) in patients with IC (Fontaine stage II) receiving oral buflomedil compared with
placebo. Pain-free walking distance (PFWD) and maximum walking distance (MWD) were analysed by standardized exercise test.
Data collection and analysis
Two authors independently assessed trial quality and extracted data. We contacted study authors for additional information.
Main results
We included two RCTs with 127 participants. Both RCTs showed moderate improvements in PFWD for patients on buflomedil. This
improvement was statistically significant for both trials (WMD 75.1 m, 95% confidence interval (CI) 20.6 to 129.6; WMD 80.6 m,
95% CI 3.0 to 158.2), the latter being a wholly diabetic population. For both RCTs, MWD gains were statistically significant with
wide confidence intervals (WMD 80.7 m, 95% CI 9.4 to 152; WMD 171.4 m, 95% CI 51.3 to 291.5), respectively.
Authors’ conclusions
There is little evidence available to evaluate the efficacy of buflomedil for IC. Most trials were excluded due to poor quality. The two
included trials showed moderately positive results; these are undermined by publication bias since we know of at least another four
unpublished, irretrievable, and inconclusive studies.
Buflomedil’s benefit is small in relation to safety issues and its narrow therapeutic range.
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P L A I N L A N G U A G E S U M M A R Y
Buflomedil for intermittent claudication
Intermittent claudication (IC) is pain that develops in a limb (mostly calves and thighs) during exercise and is relieved with rest. It is
caused by insufficient blood flow due to peripheral arterial occlusive disease.
Treatment should contain all measures of secondary prevention of cardiovascular diseases. Regular exercise and smoking cessation is
the most effective therapy to improve the symptoms of claudication. Drug treatments include vasoactive agents to improve blood flow
(such as vasodilators and other hemorheologic agents that reduce blood viscosity), anticoagulants, antiplatelet agents and lipid-lowering
agents. Only a minority of patients undergo angioplasty or vascular surgery.
Buflomedil is a vasoactive agent widely used to treat intermittent claudication. The review authors identified eleven trials but could not
use nine of them because of the methodologies used and high risk of bias. The two remaining controlled trials randomised a total of
127 participants to receive buflomedil or placebo for at least three months. One of these trials involved 40 participants with diabetes.
Taken together, the trials showed moderately positive results for improvements in pain-free walking distance on a treadmill (76.9 m,
95% CI 32.3 to 121.5) and maximum walking distance (112.6 m, 95% 27.7 to 197.5) with buflomedil for 12 weeks, showing a wide
variation in benefit between participants.
The excluded studies consisted of three small marginally positive studies and one larger negative study. At least another four unpublished
studies could not be retrieved and were reported to have inconclusive results.
Recent safety concerns have been raised about buflomedil because of lethal and non-lethal neurologic and cardiovascular advents events
in cases of accidental and voluntary overdoses.
The benefit of buflomedil is small in light of relatively little evidence on efficacy and narrow therapeutic range along with recent safety
issues.
B A C K G R O U N D
Description of the condition
Chronic occlusive arterial disease of the lower extremities can
present itself in different ways:
1. asymptomatic arterial insufficiency;
2. symptomatic disease presenting as intermittent
claudication, i.e. pain that develops in the affected limb with
exercise and is relieved with rest;
3. rest pain with, or without, atrophic skin disorders;
4. critical leg ischemia, in which the ischemic process
endangers part or all of the lower extremity.
Atherosclerosis is the most common cause of chronic arterial oc-
clusive disease of the lower extremities. It causes arterial narrowing,
or occlusion, which reduces blood flow to the lower limb during
exercise or at rest. In the clinical condition of intermittent claudi-
cation, the severity of the symptoms depends upon the extent of
the narrowing and the collateral circulation.
Description of the intervention
Patients with intermittent claudication are most often managed
conservatively. Only a minority (10% to 25%) (Verhaeghe 1998)
of the patients undergo angioplasty or vascular surgery. Regular ex-
ercise (Leng 2000) and smoking cessation can improve the symp-
toms of claudication and may be beneficial for the often associated
coronary artery or cerebrovascular disease or both.
Conservative treatment should achieve:
1. improvement of functional capacity, i.e. an increase in
walking distance;
2. inhibition of progression of atherosclerotic lesions;
3. reduction of cardiac and cerebrovascular morbidity and
mortality.
Many types of drugs are used in the treatment of intermittent
claudication: vasoactive agents (vasodilators and hemorheologic
agents), antithrombotic agents, antiplatelet agents, lipid-lowering
agents. Trials have also been performed with vitamin E (Kleijnen
1998), garlic (Jepson 1997) and sex hormones (Price 2001) with
varying results.
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How the intervention might work
Vasodilators cause vasodilation in the arterioles of the lower limbs.
However, they are thought to be ineffective because large vessel
dimensions are fixed by the atherosclerotic process and collaterals
are already maximally dilated in patients with intermittent claudi-
cation. Sometimes vasodilators may evenworsen ischemia due to a
’steal’ phenomenon. Hence, the interest has shifted from vasodila-
tors to drugs that improve flow by altering viscosity. Decreased
erythrocyte deformability and abnormal whole blood viscosity are
present in patients with peripheral arterial disease and offer poten-
tial therapeutic targets for agents that affect viscosity (hemorheo-
logic agents). One of these agents is buflomedil, for which bene-
ficial effects on microcirculation of the legs and on cerebral blood
flow in patients with cerebrovascular disease have been claimed.
Pathophysiological research has shown that buflomedil inhibits
platelet aggregation, may improve red cell deformability and re-
duces whole blood and plasma viscosity by reducing plasma fib-
rinogen (Bevan 1992).
Why it is important to do this review
Buflomedil was registered before the era of rigorous regulatory
review and was accepted for peripheral arterial occlusive disease
(PAOD) and for cerebrovascular disease. Its exact market for these
two indications is not known but is predominantly for PAOD.
The product is still widely used. Health insurers in many countries
have become increasingly critical of the efficacy of this product and
sometimes have restricted or abolished reimbursement. Therefore,
a reassessment of the efficacy of this product is timely.
O B J E C T I V E S
To collect and to evaluate systematically the available evidence
from placebo-controlled, double-blind randomized controlled tri-
als (RCTs) on the efficacy of buflomedil, given orally, in inter-
mittent claudication (Fontaine stage II) (Fontaine 1954), by mea-
suring the pain-free walking distance (PFWD) and the maximum
walking distance (MWD), with a standardized treadmill test.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Included studies were prospective, randomized, double blind,
placebo-controlled, parallel or cross-over trials involving more
than 30 participants. For cross-over studies, only the first period
of the cross over was considered (Cameron 1988).
Types of participants
Patients with intermittent claudication in Fontaine-stage II (with
the criteria explicitly described), regardless of duration of onset
or smoking status. Studies including patients with inflammatory
arteriopathy, thromboangiitis obliterans, acute ischemia, purely
neuropathic ulceration or gangrene necessitating immediate am-
putation and attempted reconstruction or sympathectomy within
the preceding three months or both were excluded.
Types of interventions
Interventions using buflomedil orally in doses of 300 mg to 900
mg per day, compared with a placebo control group.
Types of outcome measures
Primary outcomes
The primary outcome measure was the pain-free walking distance
(PFWD), assessed by treadmill exercise using prespecified criteria,
with a minimum of three months duration between baseline and
outcome assessment.
Secondary outcomes
The secondary outcome measure was the maximum walking dis-
tance (MWD).
Search methods for identification of studies
Electronic searches
For this update the Cochrane Peripheral Vascular Diseases Group
Trials Search Co-ordinator (TSC) searched the Specialised Regis-
ter (last searched January 2013) and the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL) 2012, Issue 12, part of The
Cochrane Library (www.thecochranelibrary.com). See (Appendix
1) for details of the search strategy used to search CENTRAL.
The Specialised Register is maintained by the TSC and is con-
structed from weekly electronic searches of MEDLINE, EM-
BASE, CINAHL, AMED, and through handsearching relevant
journals. The full list of the databases, journals and conference
proceedings which have been searched, as well as the search strate-
gies used are described in the (Specialised Register) section of
the Cochrane Peripheral Vascular Diseases Group module in The
Cochrane Library (www.thecochranelibrary.com).
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Searching other resources
Authors’ searches
For the original review the authors searched MEDLINE for the
free text string ’buflomedil’. To identify randomized controlled
trials (RCTs) we first used the systematic search strategy suggested
by the Cochrane Collaboration (Dickersin 1994). However, this
search was too restrictive. We then simplified our search strategy
by crossing the active ingredient namewith theMeSH term “inter-
mittent claudication”. This resulted in references to case reports,
editorials, reviews, and original study reports.We obtained the full
text of the publications pertaining to intermittent claudication and
checked their reference lists for additional studies. We consulted
the International Pharmaceutical Abstracts. We asked Abbott, the
distributor of the drug, to provide reports of controlled clinical
trials available to them. From this pool of studies we extracted the
placebo-controlled RCTs matching our criteria for patient selec-
tion, intervention and outcome (PIO-criteria). We finally submit-
ted a core of relevant articles to a Science Citation Index search.
Data collection and analysis
Selection of trials
Initially, we attempted to construct a data file of individual patients
with a predefined list of variables. However this failed because we
were unable to retrieve individual data, either by extraction from
the published report or by seeking direct access to the original
data from the authors. Hence, data extraction was performed on
aggregated data for walking distances, as published in the study
reports.
Assessment of methodological quality
The set of retrieved trials, complying with our inclusion criteria,
was then subjected to a quality assessment.
Structured abstractsweremade of every original article retrieved, in
order to facilitate the collective quality evaluation process among
the three authors. Three authors (TDB, RVS, MGB) indepen-
dently assessed articles, structured abstracts and checklists. Dis-
crepancies were discussed until consensus was reached. In a first
round of quality assessment, we used the minimal quality criteria
for PAOD trials described by Cameron et al (Cameron 1988): i.e.
minimum of three months duration between baseline and out-
come assessment, not less than thirty participants in total, and
sufficient detail in reporting of variability of results (standard de-
viation or standard error of the mean given). The studies were also
submitted to a more fundamental assessment of internal validity,
according to the model of Schulz (Schulz 1995) and the model of
Jadad (Jadad 1996). According to the methodology proposed by
The Cochrane Collaboration (Mulrow 1999), studies were graded
“A” if there was a low risk of bias (no flaws in design and internal
validity), “B” if there was a moderate risk of bias and “C” if there
was a high risk of bias (major flaws in design or internal validity
or both or not conforming to the minimal criteria of Cameron)
(Cameron 1988).
In some publications, results were not reported in sufficient detail.
Attempts were made to contact the author(s) by phone, fax or e-
mail without success in all cases.
Extraction of data
We collected data on trial duration, participants’ age, sex, smoking
status, presence of diabetes comorbidity, dosage, the exclusion cri-
teria, and the location of the arterial stenosis. Finally, the dropout
rates in placebo and active limb were compared.
Statistical analysis
The evidence was summarized by extracting the mean and stan-
dard deviation of the initial and final walking distances for the
active substance and for placebo. The differences in incremental
gain between active and placebo groups for PFWD and MWD
with their confidence intervals were calculated, using an approxi-
mate method, described by Gardner and Altman (Gardner 1989a;
Gardner 1989b; Gardner 1989c; Gardner 1989d).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Eleven trials were identified as described above, but nine were
subsequently excluded.
Results of the search
Our search in the bibliographic databases resulted in the identifica-
tion of four eligible trials (Bisler 1983; Fonseca 1988; Limbs 2008;
Trübestein 1984). We also identified a meta-analysis (Walker
1995), with references to ten trials, (Baitsch 1983; Bisler 1983;
Trübestein 1984; Diamantopoulos 2001; Zinnagl 1986; Levien
1983; Lowe 1987; Lund 1988; Olsson 1986; Raithel 1985). We
were able to retrieve the full text of seven eligible RCTs, six
published (Bisler 1983; Diamantopoulos 2001; Fonseca 1988;
Limbs 2008; Trübestein 1984; Zinnagl 1986) and one unpub-
lished (Lowe 1987).The original text of one published trial was
sent to us by the primary author (Diamantopoulos 1989). This
trial was published again in 2001 (Diamantopoulos 2001). One
other published (Zinnagl 1986) trial was sent to us in full text
by one of the authors of the above mentioned meta-analysis. We
4Buflomedil for intermittent claudication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
made multiple requests for the unpublished trials (Levien 1983;
Lund 1988; Olsson 1986; Raithel 1985).
Included studies
Trübestein (published trial) (Trübestein 1984), conducted a well
designed multicenter trial with 113 patients. Twenty dropouts
were adequately described. The duration of the intervention pe-
riod was 12 weeks. There was a statistically significant increase in
PFWD and in MWD in the buflomedil group versus the placebo
group.
Diamantopoulos (published trial) (Diamantopoulos 2001), con-
ducted a rather small study (N = 40), with a wholly diabetic popu-
lation of claudicants. There were six well described dropouts. The
treatment period was six months.
Excluded studies
From the abstracts, we were able to determine that one trial
(Baitsch 1983), was not eligible because the intervention was with
intravenous treatment. Four trials were excluded because of high
risk of bias due to problems of methodological quality: the du-
ration of one trial was not long enough (Bisler 1983); the other
three trials presented problems of internal validity and failed to
give elementary details on variability of the results (Fonseca 1988;
Lowe 1987; Zinnagl 1986). Four of the excluded studies consisted
of three small marginally positive studies (Bisler 1983; Fonseca
1988; Zinnagl 1986) and one larger negative study (Lowe 1987).
We were unable to retrieve the full texts of the other four un-
published trials (Levien 1983; Lund 1988; Olsson 1986; Raithel
1985). In the Excluded studies table we summarized the available
information from these unpublished trials extracted from the ta-
bles in the meta-analysis (Walker 1995).
The multicenter LIMB trial (Limbs 2008) randomized 2,078
Fontaine stage II PAOD patients with an ABI between 0.3 and
0.8 to buflomedil 300 mg BID (150 mg twice daily in case of
Creatinine (Cr) Clearance < 40ml/min) or placebo. Baseline char-
acteristics in both groups were similar. After a median follow up
of 2.75 years, patients on buflomedil (1,043 patients) had fewer
lower limb amputations, cardiovascular death and total death com-
pared to patients on placebo (1,035 patients) (9% versus 12%).
Patients on buflomedil had significant improvement in pain-free
walking distance compared to controls (median increase of PFWD
of 43% versus 0%). The drug was well tolerated. Dr Jeffrey W
Olin of Mount Sinai School of Medicine, New York, NY, criti-
cized the findings in the trial by pointing out potential confounds
and sources of error: low to zero placebo effect; 62% of patients
were Russian, with the rest distributed among the Czech Repub-
lic, France and Hungary; no information to assess internal valid-
ity; measurement of ABI questioned; WD clinically estimated (no
treadmill) (Wood 2005). The study raises many questions on the
performance, results and reporting of the study. Since the author
did not respond, many questions still remain unanswered.
Risk of bias in included studies
The two included trials (Diamantopoulos 2001; Trübestein 1984)
were both rated “B” (moderate risk of bias) because neither would
stand up tomodern standards of performing and reporting clinical
trials.
Effects of interventions
Trübestein 1984: Patients assessed their walking ability as im-
proved and the sensation after physical stress as diminished. The
authors only report a statistically significant increase in PFWD (P
< 0.001) and MWD (P < 0.01) in the buflomedil group versus
placebo group was found between the first (pre-trial) and fifth (af-
ter 84 days of treatment) examinations. The arithmetic means of
the pressure difference (brachial artery-posterior tibial artery) in
the placebo and in the buflomedil group both showed a decrease
when the first and fifth visits were compared.
Diamantopoulos 2001: The patients showed significant differ-
ences at the 5% level in mean increases in walking distances be-
tween the two groups at the three month examination. Mean in-
creases over baseline in PFWD for the buflomedil and placebo
groups were 52.8 m and 8.6 m respectively (P = 0.018) and for
MWD 81.1 m and 8.8 m respectively (P = 0.022). The mean
increases in both groups in PFWD at six months over baseline
were not significantly different (P = 0.059) even though the actual
difference was substantial (112.20 m for buflomedil; 31.6 m for
placebo). The mean increases in MWD at six months showed a
statistically significant difference (P = 0.011) (191.9 m for bu-
flomedil; 20.5 m for placebo). The systolic blood pressure indices
at rest and after exercise showed no statistically significant differ-
ences between the groups. No statistically or clinically significant
changes were noted in any hematological or biochemical values.
The drug was well tolerated by all patients and only minor side
effects were observed during the six months of treatment. All par-
ticipants in this trial were diabetic.
The two RCTs accepted after quality evaluation (Trübestein 1984;
Diamantopoulos 2001) showedmoderately positive results for the
PFWD: (WMD 75.1 m, 95% CI 20.6 to 129.6; WMD 80.6
m, 95% CI 3.0 to 158.2) metres gain of active (buflomedil) over
placebo, respectively. The gains in maximum walking distance
(MWD) were (WMD 80.7 m, 95% CI 9.4 to 152; WMD 171.4
m, 95% CI 51.3 to 291.5), respectively. Both results were statisti-
cally significant but had wide confidence intervals. Pooling of data
could not be performed because only two studies conducted in
heterogeneous populations were included.
D I S C U S S I O N
Only randomized placebo-controlled trials were considered for
this systematic review because the course of intermittent claudi-
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cation is highly variable and there is no gold standard for phar-
macological treatment of this condition. We chose the standard-
ized treadmill test as the common outcome measure because it is
the best available method tomeasure relevant endpoints (pain-free
and/or maximum walking distances/times). Also, it is the most
universal measure in studies in this research field although its value
has been criticized (Wurzinger 1987). Studies on endpoints such as
blood flow, blood viscosity, ankle/arm index, platelet aggregation,
etc. are of interest, but the clinical relevance of changes of such
endpoints by medication is not known and no correlation can be
found between the clinical parameters and these surrogate end-
points (Wurzinger 1987). To the best of our knowledge, studies
having mortality or amputation rate as endpoints do not exist. In
any case, these would require a huge sample size because of the low
frequency of these events in PAOD. Quality of life would be an
interesting outcome measure. A disease-specific questionnaire, the
CLAU-S scale, has been developed (Spengel 1997), and applied
as an endpoint in the evaluation of naftidrofuryl versus placebo
(Liard 1997). However, after careful scrutiny of the validity of the
CLAU-S scale, we did not consider it to be a convincing instru-
ment for the measurement of quality of life because it has not yet
been validated against the standardized treadmill test. The CLAU-
S scale has not been used in studies with buflomedil.
Our quality evaluation of the trials was pragmatic because most of
the retrieved trials dated from before 1992 and did not conform
to the modern quality criteria of conducting and reporting RCTs
(Jadad 1996; Schulz 1995).
Only two more-or-less acceptable studies were included. There
was large heterogeneity between patient groups in the included
and excluded studies. The lack of information on the patients
included, the small sample sizes and the small number of trials did
not allow relevant subgroup analysis.
Pooling of the data could not be performed in that only two studies
with heterogeneous populations were included.
InWalker andMacHannaford’smeta-analysis (Walker 1995), nine
heterogeneous studies were pooled, of which two studies (the same
two as included in our analysis) showed a statistically significant
difference. The remaining seven studies in theirmeta-analysis were
not statistically significant; two were published trials excluded by
us because of problems of internal validity; one trial was unpub-
lished but retrieved by us from the author and subsequently ex-
cluded again because of problems of internal validity; four trials
were unpublished, with only scant information about the quality
of execution of the trial and on the variability of the results. The
pooled effect size weighted for sample size of these nine studies
was 0.27 (CI 0.11 to 0.42) for pain-free walking distance and 0.28
(0.12 to 0.45) for maximum walking distance, which cannot be
considered as a convincing indication of efficacy.
It is unlikely that we have missed studies with a positive result in
our quest for evidence. We know of the existence of four unpub-
lished buflomedil trials (Levien 1983; Lund 1988; Olsson 1986;
Raithel 1985) which were cited in a meta-analysis (Walker 1995).
After examination of the effect sizes of these unpublished trials as
reported in this meta-analysis, their results can be considered to
be inconclusive. This contrasts with the approach and optimistic
conclusions of the meta-analysis of Walker and Mac Hannaford
(Walker 1995).
Hence, we concluded that under these circumstances statistical
pooling is not appropriate and that the evidence on the efficacy of
buflomedil is insufficient, and affected by publication bias.
Also recently the safety of buflomedil came into attention. In 2006,
a safety crisis emerged in France concerning lethal and non-lethal
neurological and cardiovascular advents events in cases of acciden-
tal and voluntary overdoses with buflomedil, mainly with the 300
mg dosage form (Marimbert 2006).
As a consequence, a number of regulatory actions were taken in
France (Marimbert 2006):
1. Change in toxicology information:
◦ Minimal toxic dose: 3 gram
◦ Lethal dose: 6 gram.
2. Withdrawal of the 300 mg dosage form, with only 150 mg
tablets still available on the market.
3. Deletion of the indication Raynaud phenomenon. Only
indication: symptomatic treatment of intermittent claudication.
4. Classification as drug with narrow therapeutic range.
5. Contra-indication in severe renal insufficiency (Cr
Clearance < 30 ml/min).
6. Posology: adaptation of the dose in mild to moderate renal
insufficiency (Cr Clearance 30 to 80 ml/min): 1 tablet of 150 mg
in the morning and evening, control of renal function before and
at regular intervals during treatment, each time recall the adverse
neurological and cardiovascular effects in case of no respect or no
adaptation of dose in renal insufficiency.
The published trials on buflomedil do not mention numerical sa-
fety data, suitable for systematic appraisal. The absence of adverse
event data from clinical trials might indicate that the drug is well
tolerated within clinical trials, as a number of authors conclude.
However, we consulted the international literature and overviews
of reported adverse events for regulatory purposes with the follow-
ing results.
a) The international literature
The terms which were used to search PUBMED are described in
Appendix 2.
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Forty- three articles were retrieved, of which 30 were relevant, 10
of which reported on fatal accidents.
From this literature search it is obvious that accidental or voluntary
overdose with buflomedil is dangerous. The drug is toxic at doses
as low as 3 gram and potentially fatal at moderate doses of 6 gram,
with kidney insufficiency as an aggravating factor.
b) Overview of reported adverse events for regulatory purposes
(database from May 1979 through to December 2006).
Sixty-five individual reports describing 102 adverse events of in-
terest were identified. Eighty-six percent of all reports came from
European countries (in descending order of number of reports:
France, Belgium, Germany, Italy, Spain, Greece, Portugal and
Switzerland). Nineteen of the 102 events were fatal. Death oc-
curred from cardiac rhythm disturbances and epileptic insults.
Of the 65 patients reported, 24 had taken an overdose (10 of
which patients attempting suicide, and the others chronic users on
normal dose but not adjusted to renal status), with serious cardiac
and neurological complications. Forty-one of the 65 patients were
on normal doses and experienced non-specific tachycardia and
hypotension expected with vasodilator therapy.
The worldwide reporting rates per 100,000 PTY between 1 De-
cember 1994 and 30 November 2006 were 0.27 for suicide, 0.82
for overdose, and 0.48 for fatalities; this reflects a total of 2.9 mil-
lion patient years.
Our statement on the negative balance between risk and benefit of
this drug is based on the one hand on the disappointing results of
a systematic review for efficacy data and a number of case reports
of toxic effects. None of these elements were sufficient for meta-
analytic pooling.
The regulatory agencies of France and Belgium recently took regu-
latory actions with restrictions in indications and available dosage
forms (only 150 mg forms available without extended release for-
mulation). This makes it unpractical to use this drug in daily prac-
tice at the doses recommended in clinical trials (600 mg daily).
Consequently, it is difficult to prescribe buflomedil, even to pa-
tients without renal insufficiency at the doses habitually used in
the clinical trials (300 mg twice daily). Most pharmaceutical prod-
ucts on the market were 300 mg tablets. Hence, we conclude that
the balance between benefit and risk for buflomedil in the symp-
tomatic treatment of intermittent claudication is unfavourable.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For buflomedil, evidence of efficacy is scant and the moderately
positive results of two included trials are undermined by publica-
tion bias.
Positive results from a recent large trial (LIMB) were not con-
firmed.
Buflomedil has failed to document its efficacy for intermittent
claudication, despite extensive utilization and many years of field
experience.
Also due to safety concerns, indications become evenmore restric-
tive and careful monitoring is advised.
It is time to review the basis of its marketing authorization as it
still retains an appeal for patients and for prescribers, despite the
lack of evidence of efficacy and emerging safety concerns.
Implications for research
To refute the hypothesis that buflomedil is not efficacious in in-
termittent claudication, additional, well executed, high quality,
placebo-controlled, double blind trials with sufficient sample sizes
need to be performed.
A C K N OW L E D G E M E N T S
Wewould like to thank ProfMGBogaert for his work on previous
versions of this review. Wewould like to thank the Cochrane Con-
sumer Network for providing an updated Plain Language Sum-
mary. We would also like to thank the Cochrane Peripheral Vas-
cular Diseases Group for their extensive assistance with the most
recent update.
7Buflomedil for intermittent claudication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Diamantopoulos 2001 {published data only}
∗ Diamantopoulos EJ, Grigoriadou M, Ifanti G, Raptis
SA. Clinical and hemorheological effects of buflomedil
in diabetic subjects with intermittent claudication.
International Angiology 2001;20(4):337–44.
Diamantopoulos EJ, Raptis SA, Christodoulou-Peters M,
Moulopoulos SD. Controlled trial of buflomedil in diabetic
peripheral occlusive disease. Ischaemic Diseases and the
Microcirculation. New Results. International Symposium.
Frankfurt, January 1989:80–4.
Trübestein 1984 {published data only}
Trubestein G, Balzer K, Bisler H, Kluken N, Mahfoud
Y, Muller-Wiefel H, et al.Buflomedil in obstructive
arterial disease: Results of a controlled trial [Buflomedil
bei arterieller Verschlusskrankheit: Ergebnissse einer
kontrollierten Studie]. Deutsche Medizinische Wochenschrift
1982;107(51-52):1957–61.
∗ Trübestein G, Balzer K, Bisler H, Klüken N, Muller-
Wiefel H, Unkel B, et al.Buflomedil in arterial occlusive
disease: results of a controlled multicenter study. Angiology
1984;35(8):500–5.
References to studies excluded from this review
Bisler 1983 {published data only}
Bisler H. Clinical response to buflomedil in arterial occlusive
disease. Therapiewoche 1983;33:2204–10.
Fonseca 1988 {published data only}
Fonseca V, Mikhaildis DP, Barradas MA, Jeremy JY, Gracey
L, Dandona P. Double-blind placebo-controlled trial of
buflomedil in intermittent claudication. International
Journal of Clinical Pharmacology Research 1988;8(5):
377–81.
Levien 1983 {published data only (unpublished sought but not used)}
Levien. [Unpublished study] W80-BU-004LJL. S-Africa,
1983. Mentioned in: Walker GA, Mac Hannaford JC.
A meta-analysis of randomized, double-blind, placebo-
controlled studies of the effect of buflomedil on intermittent
claudication. Fundamental and Clinical Pharmacology 1995;
9(4):387–94.
Limbs 2008 {published data only}
Leizorovicz A. Buflomedil reduces amputations in patients
with peripheral arterial occlusive disease. American College
of Cardiology, 54th Annual Scientific Session, Late-
Breaking Clinical Trials; 2005 Mar 6-9; Orlando, Florida
2005.
Limbs International Medicinal Buflomedil (LIMB) Study
Group, Leizorovicz, A, Becker F. Oral buflomedil in
the prevention of cardiovascular events in patients with
peripheral arterial obstructive disease: a randomized,
placebo-controlled, 4-year study.[see comment]. Circulation
2008;117(6):816–22.
Lowe 1987 {unpublished data only}
Lowe GDO, Dandona P, Horrocks M, Cotton LT.
[Unpublished study] Evaluation of the clinical efficacy and
safety of oral buflomedil hydrochloride in the treatment
of intermittent claudication. Study QL/UK.83/2-5. UK,
1987. Mentioned in: Walker GA, Mac Hannaford JC.
A meta-analysis of randomized, double-blind, placebo-
controlled studies of the effect of buflomedil on intermittent
claudication. Fundamental and Clinical Pharmacology 1995;
9(4):387-94 (Available from the authors).
Lund 1988 {published data only (unpublished sought but not used)}
Lund, et al.[Unpublished study] AB-8603. US, 1988.
Mentioned in: Walker GA, Mac Hannaford JC. A meta-
analysis of randomized, double-blind, placebo-controlled
studies of the effect of buflomedil on intermittent
claudication. Fundamental and Clinical Pharmacology 1995;
9(4):387–94.
Olsson 1986 {published data only (unpublished sought but not used)}
Olsson. [Unpublished study] Sweden, 1986. Mentioned
in: Walker GA, Mac Hannaford JC. A meta-analysis of
randomized, double-blind, placebo-controlled studies of
the effect of buflomedil on intermittent claudication.
Fundamental and Clinical Pharmacology 1995;9(4):387–94.
Raithel 1985 {published data only (unpublished sought but not used)}
Raithel, et al.[Unpublished study] BU-3-P05. Germany,
1985. Mentioned in: Walker GA, Mac Hannaford JC.
A meta-analysis of randomized, double-blind, placebo-
controlled studies of the effect of buflomedil on intermittent
claudication. Fundamental and Clinical Pharmacology 1995;
9(4):387–94.
Zinnagl 1986 {published data only}
Zinnagl N. A double blind study of the effects of buflomedil
in 40 patients with arterial occlusive disease in Stage IIB
[Doppelblindstudie über die Wirksamkeit von Buflomedil
an 40 Patienten mit arterieller Verschlusskrankheit im
Stadium IIB]. International Symposium on Conservative
Therapy of Arterial Occlusive Disease. Bonn, May 23-25.
New York: Georg Thieme Verlag, 1986.
Additional references
Baitsch 1983
Baitsch R. [Unpublished study]. BU-2-DO2. Germany,
1983. Mentioned in: Walker GA, Mac Hannaford JC.
A meta-analysis of randomized, double-blind, placebo-
controlled studies of the effect of buflomedil on intermittent
claudication. Fundamental and Clinical Pharmacology
1995; Vol. 9, issue 4:387–94.
Bevan 1992
Bevan EG, Waller PC, Ramsay LE. Pharmacological
approaches to the treatment of intermittent claudication.
Drugs and Aging 1992;2(2):125–36.
Cameron 1988
Cameron HA, Waller PC, Ramsay LE. Drug treatment of
intermittent claudication: critical analysis of the methods
8Buflomedil for intermittent claudication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and findings of published clinical trials, 1965-1985. British
Journal of Clinical Pharmacology 1988;26(5):569–76.
Diamantopoulos 1989
Diamantopoulos EJ, Raptis SA, Christodoulou-Peters M,
Moulopoulos SD. Controlled trial of buflomedil in diabetic
peripheral occlusive disease. Ischaemic diseases and the
microcirculation. New results. International Symposium.
Frankfurt, January 1989:80–4.
Dickersin 1994
Dickersin K, Scherer R, Lefebvre C. Identifying relevant
studies for systematic reviews. BMJ 1994;309(6964):
1286–91.
Fontaine 1954
Fontaine VR, Kim M, Kieny R. Surgical treatment for
peripheral vascular disease [Die chirurgische Behandlung
der peripheren Durchblutungsstorungen]. Helvetica
Chirurgica Acta 1954;5/6:499–533.
Gardner 1989a
Gardner MJ, Altman DG. Estimating with confidence.
In: Gardner MJ, Altman DG editor(s). Statistics with
confidence: confidence intervals and statistical guidelines.
London: BMJ Publishing Group, 1989:3–5.
Gardner 1989b
Gardner MJ, Altman DG. Estimation rather than
hypothesis testing: confidence intervals rather than P
values. In: Gardner MJ, Altman DG editor(s). Statistics
with confidence: confidence intervals and statistical guidelines.
London: BMJ Publishing Group, 1989:6–19.
Gardner 1989c
Altman DG, Gardner MJ. Calculating confidence intervals
for means and their differences. In: Gardner MJ, Altman
DG editor(s). Statistics with confidence: confidence intervals
and statistical guidelines. London: BMJ Publishing Group,
1989:20–7.
Gardner 1989d
Gardner MJ, Altman DG. Tables for calculation of
confidence intervals. In: GardnerMJ, Altman DG editor(s).
Statistics with confidence: confidence intervals and statistical
guidelines. London: BMJ Publishing Group, 1989:111–29.
Jadad 1996
Jadad RJ, Moore RA, Carroll D, Jenkinson C, Reynolds
DJ, Gavaghan DJ, et al.Assessing the quality of reports of
randomized clinical trials: is blinding necessary?. Controlled
Clinical Trials 1996;17:1–12.
Jepson 1997
Jepson RG, Kleijnen J, Leng GC. Garlic for peripheral
arterial occlusive disease. Cochrane Database of
Systematic Reviews 2006, Issue 2. [DOI: 10.1002/
14651858.CD000095]
Kleijnen 1998
Kleijnen J, Mackerras D. Vitamin E for intermittent
claudication. Cochrane Database of Systematic Reviews 1998,
Issue 1. [DOI: 10.1002/14651858.CD000987]
Leng 2000
Leng GC, Fowler B, Ernst E. Exercise for intermittent
claudication. Cochrane Database of Systematic Reviews 2000,
Issue 2. [DOI: 10.1002/14651858.CD000990]
Liard 1997
Liard F, Benichou AC, Gamand S, Lehert P. The effects of
naftidrofuryl on quality of life. Disease Management Health
Outcomes 1997;2(Suppl 1):71–8.
Marimbert 2006
Marimbert J. Lettre aux professionnels de santé:
Pharmacovigilance et la sécurité d’emploi du buflomédil
[Letter to health professionals: Pharmacovigilance and
safety of use of buflomedil]. Agence française de sécurité
sanitaire des produits de santé. 13 November 2006.
Mulrow 1999
Mulrow CD, Oxman AD. Cochrane Collaboration Handbook
(In: The Cochrane Library, Issue 3). Oxford: Update
Software, 1999.
Price 2001
Price JF, Leng GC. Steroid sex hormones for lower limb
atherosclerosis. Cochrane Database of Systematic Reviews
2005, Issue 3. [DOI: 10.1002/14651858.CD000188]
Schulz 1995
Schulz KF, Chalmers IC, Hayes RJ, Altman DG. Empirical
evidence of bias. Dimensions of methodological quality
associated with estimates of treatment effects in controlled
trials. Journal of the American Medical Association 1995;273
(5):408–12.
Spengel 1997
Spengel A, Brown TM, Dietze S, Kirchberger I, Comte
S. The claudication scale (CLAU-S). New disease-specific
quality-of-life instrument in intermittent claudication.
Disease Management Health Outcomes 1997;2(Suppl 1):
65–70.
Verhaeghe 1998
Verhaeghe R. Epidemiology and prognosis of peripheral
obliterative arteriopathy. Drugs 1998;56(suppl 3):1–10.
Walker 1995
Walker GA, Mac Hannaford JC. A meta-analysis of
randomized, double-blind, placebo-controlled studies of
the effect of buflomedil on intermittent claudication.
Fundamental and Clinical Pharmacology 1995;9(4):387–94.
Wood 2005
Wood S. Buflomedil to reduce clinical complications
of peripheral artery disease? Maybe, maybe not.
www.theheart.org/article/402581.do 11 March 2005, issue
accessed 26 April 2007.
Wurzinger 1987
Wurzinger LJ, Schmid-Schonbein H. Effect of buflomedil
on epinephrine-enhanced platelet aggregation in vitro and
ex vivo. Arzneimittel-Forschung 1987;37(10):1113–5.
References to other published versions of this review
9Buflomedil for intermittent claudication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
De Backer 2000
De Backer TLM, Vander Stichele RH, Bogaert MG.
Buflomedil for intermittent claudication. Cochrane
Database of Systematic Reviews 2000, Issue 2. [DOI:
10.1002/14651858.CD000988]
De Backer 2007
De Backer TLM, Bogaert MG, Vander Stichele RH.
Buflomedil for intermittent claudication. Cochrane
Database of Systematic Reviews 2007, Issue 4. [DOI:
10.1002/14651858.CD000988.pub2]
de Backer 2008
de Backer TLM, Bogaert M, Vander Stichele R. Buflomedil
for intermittent claudication. Cochrane Database of
Systematic Reviews 2008, Issue 1. [DOI: 10.1002/
14651858.CD000988.pub3]
∗ Indicates the major publication for the study
10Buflomedil for intermittent claudication (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Diamantopoulos 2001
Methods Study design: States randomized, double-blinded.
Method of randomization: Not stated.
Blinding: Double-blinded.
Dropouts: 2 patients from the buflomedil group, because they felt better, and 4 from the




No. 40 patients; (21 buflomedil, 19 placebo).
Gender: 36 males (19 buflomedil, 17 placebo), 4 females (2 buflomedil, 2 placebo)
Age: mean 60.1 years (range 39 to 77).
Inclusion criteria: All had maturity onset diabetes mellitus (11 insulin-dependent,
29 non-insulin dependent, mean duration 14 years) mean duration PAOD 3.4 years,
walking distance < 400 m SBP indices at both ankles estimated by Doppler
At the start of a 4-week observation period before entry into the study, patients were given
a full physical examination and an ECG at rest and after exercise on a treadmill (3.6 km/h
at 12.5°C)
Exclusion criteria: Vascular surgery or specific physical training, participation in another
study, history of cerebrovascular accident or coronary heart disease, concomitant therapy
that could influence any of the parameters to be studied, evidence of excessive Moncke-
berg’s sclerosis, diabetic retinopathy, severe renal, hepatic or cardiopulmonary impairment,
uncontrolled arterial hypertension, previous AMI, angina pectoris, severe cardiac arrhyth-
mias, evidence of peripheral sensory neuropathy, arterial bleeding, pregnancy or lactation,
allergy to any medication, history of convulsions or other central nervous system diseases,
grossly over- or under-weight diabetics based on tables size-weight, musculoskeletal disor-
ders limiting walking ability
Interventions Treatment: During 6 month treatment period patients received 600 mg buflomedil per
day, 2 x 150 mg tablets taken twice a day
Control: Matching placebo tablets.
Compliance checked every 3 to 4 weeks by patients returning their bottles to the outpatient
clinic where remaining tablets were counted
Duration: Six months.
Outcomes Primary: Distances at 6 months constituted the primary response variables. PFWD and
MWDmeasured at entry (baseline) and after 3 and 6 months’ treatment using a standard-
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Diamantopoulos 2001 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Trübestein 1984
Methods Study design: States randomized, double-blinded.
Method of randomization: Not stated.
Blinding: Double-blinded.
Dropouts: 8 in the placebo group and 12 in the buflomedil group, leaving 93 for analysis




Age: 50 to 70 years old.
Gender: Not stated.
Inclusion criteria: Symptoms of intermittent claudication for 6 months to 5 years and
PFWD of 50 to 400 m
After a four-week run-in period during which all patients received placebo and other
vasoactive drugs were stopped, patients were checked to test whether their PFWD differed
by not more than 30% from the value at the beginning of the run-in period (mean of two
consecutive measurements). Patients were then allocated randomly to treatment groups
Exclusion criteria: Special physical training for at least sixmonths prior to study start; systolic
blood pressure at the ankle of less than 70 mm Hg, diabetic microangiopathy or necrosis,
inflammatory vascular disease such as endarteritis obliterans, coronary heart disease with
angina pectoris, myocardial insufficiency, respiratory insufficiency, arthropathy, symptoms
of severe liver or kidney disease, laboratory values of more than 10% outside normal range,
pregnancy, beta-blockers and any other vasoactive drugs
Interventions All patients received placebo tablets (four daily - 2 in the morning, one at midday and one
in the evening) for four weeks run-in
Treatment: Buflomedil 600 mg daily (2 x 150 mg in the morning, 1 x 150 mg at midday
and 1 x 150mg in the evening.)
Control: Matching placebo.
Duration: 12 weeks treatment.
(16 weeks in total including the 4 week run-in period.)
Outcomes Primary: PFWD and MWD were measured by treadmill (5 km/h at 10° elevation)
Ankle-arm pressures were measured by Doppler at rest and after exercise and pressure
differences (brachial artery-posterior tibial artery) were calculated
Measurements were performed at days 28, 56, and 84.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Trübestein 1984 (Continued)
Allocation concealment (selection bias) Unclear risk B - Unclear
AMI: acute myocardial infarction
ECG: electrocardiogram
MWD: maximal walking distance
PAOD: peripheral arterial occlusive disease
PFWD: pain-free walking distance
SBP: systolic blood pressure
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bisler 1983 A small study (N = 38) with a mixed protocol of 14 days intravenous therapy (2 x 100 mg) followed by eight weeks
oral therapy (daily dose of 600 mg in three doses. The duration of the study was too short (8 weeks) for inclusion. At
randomization there were 20 participants in the active group versus 18 in the placebo group. Percentages of smokers
and diabetics were not given. No mention of: dropouts, total number of patients screened, or how many of the
original 38 patients completed the study
Fonseca 1988 A small study (N = 34) with six poorly described dropouts (two in the active group, four in the placebo group).
23% of participants were diabetic. Daily dosage of 600 mg given in two doses. The primary aim of the study was
to investigate whether buflomedil inhibits platelet aggregation in patients with PAOD. The secondary endpoints
were PFWD, MWD and subjective improvement. The results of the primary endpoint were negative and so the
researchers shifted attention to the secondary outcomes. Results of treadmill tests expressed in time units and not in
distance units. Standard deviations of results not given
Levien 1983 Study 08 in the meta-analysis of Walker and Mac Hannaford, but not published. Twenty-six participants with a
mean age of 63 years, treated for six months with 600 mg of buflomedil or placebo. An effect size of -0.5 to 1.2
mentioned. We could not obtain this study. Example of publication bias
Limbs 2008 Although this is a large, double-blind RCT, we excluded this study because PFWD and MWD were not measured
by an objective standardized test. See Table 1 for details of the trial.
Lowe 1987 Unpublished multicenter study mentioned in the meta-analysis of Walker and Mac Hannaford. We obtained this
trial as confidential material with the help of the Cochrane PVD Group. The trial was rather short (12 weeks),
daily dosage of 600 mg given in three doses, and results did not provide statistics on variation (SD or SEM). At
randomization there were 97 participants in the active group versus 104 in the placebo group. Dropouts (29 in active
group and 25 in placebo group) and protocol violations were mentioned but not well described. This study clearly
showed negative results for the PFWD
Lund 1988 Study 11 in the meta-analysis of Walker and Mac Hannaford, but not published. One hundred and sixty-eight
participants were treated for three months with 600 mg of buflomedil or placebo. We could not retrieve this study.
Example of publication bias
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(Continued)
Olsson 1986 Study 10 in the meta-analysis of Walker and Mac Hannaford, but not published. Sixty patients (mean age?) partici-
pated in this study and were treated for three months. An effect size of -0.3 to 07 was given. We could not retrieve
this study. Example of publication bias
Raithel 1985 Study 09 in the meta-analysis of Walker and Mac Hannaford, but not published. One hundred and five participants
were treated for four months with a daily dose of 600 mg buflomedil or placebo. An effect size of -0.2 to 0.6 was
given. We could not obtain this study. Example of publication bias
Zinnagl 1986 A small study (N = 40), with a short double blind phase of 60 days, inadequate reporting of trial procedures, and no
data on variability of results. Total daily dosage was 600 mg given in four doses. Percentages of smokers and diabetics
were not given. At randomization there were 20 participants in each group and there were no dropouts
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D A T A A N D A N A L Y S E S
Comparison 1. Buflomedil versus placebo




participants Statistical method Effect size
1 Painfree walking distance.
Meters gain
2 127 Mean Difference (IV, Random, 95% CI) 76.92 [32.32, 121.
52]
2 Maximal walking distance.
Meters gain
2 127 Mean Difference (IV, Random, 95% CI) 112.64 [27.73, 197.
54]
Analysis 1.1. Comparison 1 Buflomedil versus placebo, Outcome 1 Painfree walking distance. Meters gain.
Review: Buflomedil for intermittent claudication
Comparison: 1 Buflomedil versus placebo
Outcome: 1 Painfree walking distance. Meters gain





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Diamantopoulos 2001 19 112.2 (162.6) 15 31.6 (51.4) 33.0 % 80.60 [ 3.00, 158.20 ]
Tru¨bestein 1984 47 114.3 (167.5) 46 39.2 (90.07) 67.0 % 75.10 [ 20.60, 129.60 ]
Total (95% CI) 66 61 100.0 % 76.92 [ 32.32, 121.52 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 3.38 (P = 0.00072)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
Favours placebo Favours buflomedil
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Analysis 1.2. Comparison 1 Buflomedil versus placebo, Outcome 2 Maximal walking distance. Meters gain.
Review: Buflomedil for intermittent claudication
Comparison: 1 Buflomedil versus placebo
Outcome: 2 Maximal walking distance. Meters gain





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Diamantopoulos 2001 19 191.9 (237.8) 15 20.5 (108.2) 35.2 % 171.40 [ 51.27, 291.53 ]
Tru¨bestein 1984 47 141.3 (191.25) 46 60.6 (158.36) 64.8 % 80.70 [ 9.40, 152.00 ]
Total (95% CI) 66 61 100.0 % 112.64 [ 27.73, 197.54 ]
Heterogeneity: Tau2 = 1573.18; Chi2 = 1.62, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 2.60 (P = 0.0093)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
Favours placebo Favours buflomedil
A D D I T I O N A L T A B L E S
Table 1. Limbs 2008 trial
Methods Study design: international, multicenter, randomized, placebo-controlled, double-blinded
Participating centers: Czech Republic, France, Hungary, Russia
Method of randomization:a centralized computer-generated schedule (1:1 randomization in blocks of 6 and stratified
by center and creatinine clearance)
Blinding:double-blind; buflomedil and placebo were indistinguishable in terms of shape, smell and appearance
Statistical analysis: primary efficacy outcome performed on the intention-to-treat population; safety analysis per-
formed on the as-treated population;
Dropouts:buflomedil: 223 patients permanently stopped treatment prior to study completion (including death)
and 5 patients lost to follow-up; placebo: 219 patients permanently stopped treatment prior to study completion
(including death) and 10 patients lost to follow-up
Participants Patients > 40 y with documented peripheral arterial obstructive disease, intermittent claudication, and an ankle-
brachial index between 0,30 and 0,80
Patientswere excluded from the study if they presented the following characteristics: ischemic rest pain (i.e., Fontaine’s
stage III PAD), ulceration or gangrene (i.e., Fontaine’s stage IV PAD), iliac or common femoral artery stenosis or
occlusion, arterial occlusion of embolic origin, Buerger disease, or any nonatherosclerotic arterial
disease of the lower limbs. Likewise, patients with confounding factor(s) interfering with the evaluation of PAD (e.
g., major stroke sequel or major amputation of a lower limb) or the effect of the study treatment (e.g., patients in
whom vasoactive treatments could not be discontinued or who were already under treatment with buflomedil
started 1 month previously) were not recruited. Other exclusion criteria were acute myocardial infarction or stroke
within the last 45 days, vascular or endovascular surgery within the last 45 days or planned within the next month,
active cancer, poor short-term vital prognosis, and thrombophilia. Finally, pregnant or breast-feeding
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Table 1. Limbs 2008 trial (Continued)
women and women of childbearing age not using effective contraception could not participate in the study
n = 2078 patients randomized: 1043 to buflomedil, 1035 to placebo
Interventions Long-term administration (mean 33 months) of oral buflomedil or placebo
Outcomes 1. The primary efficacy outcome was critical cardiovascular events, defined as the composite of cardiovascular death
(including sudden death of presumed cardiac origin), nonfatal myocardial infarction, nonfatal stroke, symptomatic
deterioration of peripheral arterial obstructive disease, or leg amputation
2. Secondary efficacy end points included the individual components of the primary efficacy outcome, death resulting
from any cause, and all cardiovascular events. Other secondary efficacy endpoints were pain-free and maximal
walking distances (as assessed by patient questioning), ABI values, and quality of life (i.e. ability to perform daily
life activities according to the patient using a 0- to 100-mm subjective visual analogue scale)
3. The primary safety outcome was adverse events, with special attention paid to myoclonia and convulsion
Notes Although this is a large, double-blind RCT, we excluded this study because PFWD and MWD were not measured
by an objective standardized test
Because of safety reasons, oral buflomedil 300 mg tablets are not anymore on the market
From certain experts in the vascular field (Olin J, NY, USA) criticism has been made on the reliability of the study
data
An associated editorial by MS Conte (Boston, MA, USA) (Circulation 2008;117:717-9)
softened the conclusion of the LIMB study group authors that the use of buflomedil should be considered in addition
to an antiplatelet agent in patients with peripheral arterial obstructive disease and intermittent claudication
There was also a letter to the Editor (Letter by De Backer et al regarding article, “Oral buflomedil in the prevention
of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-
year study”. Circulation 2008;118;e151)
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Arteriosclerosis] this term only 893
#2 MeSH descriptor: [Arteriolosclerosis] this term only 0
#3 MeSH descriptor: [Arteriosclerosis Obliterans] this term only 71
#4 MeSH descriptor: [Atherosclerosis] this term only 382
#5 MeSH descriptor: [Arterial Occlusive Diseases] this term only 755
#6 MeSH descriptor: [Intermittent Claudication] this term only 711
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(Continued)
#7 MeSH descriptor: [Ischemia] this term only 753
#8 MeSH descriptor: [Peripheral Vascular Diseases] explode all
trees
2150
#9 MeSH descriptor: [Vascular Diseases] this term only 381
#10 MeSH descriptor: [Leg] explode all trees and with qualifiers:
[Blood supply - BS]
1073
#11 MeSH descriptor: [Femoral Artery] explode all trees 720
#12 MeSH descriptor: [Popliteal Artery] explode all trees 250
#13 MeSH descriptor: [Iliac Artery] explode all trees 151
#14 MeSH descriptor: [Tibial Arteries] explode all trees 29
#15 (atherosclero* or arteriosclero* or PVD or PAOD or PAD) 17142
#16 (arter*) near (*occlus* or steno* or obstuct* or lesio* or block*
or obliter*)
4863
#17 (vascular) near (*occlus* or steno* or obstuct* or lesio* or
block* or obliter*)
1376
#18 (vein*) near (*occlus* or steno* or obstuct* or lesio* or block*
or obliter*)
710
#19 (veno*) near (*occlus* or steno* or obstuct* or lesio* or block*
or obliter*)
976
#20 (peripher*) near (*occlus* or steno* or obstuct* or lesio* or
block* or obliter*)
1356
#21 peripheral near/3 dis* 3224
#22 arteriopathic 9
#23 (claudic* or hinken*) 1434
#24 (isch* or CLI) 16728
#25 dysvascular* 13
#26 leg near/4 (obstruct* or occlus* or steno* or block* or obliter*) 175
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(Continued)
#27 limb near/4 (obstruct* or occlus* or steno* or block* or
obliter*)
227
#28 (lower near/3 extrem*) near/4 (obstruct* or occlus* or steno*
or block* or obliter*)
136
#29 (aort* or iliac or femoral or popliteal or femoro* or fempop*
or crural) near/3 (obstruct* or occlus*)
324
#30 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or
#11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #
19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
or #28 or #29
39487
#31 buflomedil:ti,ab,kw (Word variations have been searched) 142
#32 bufedil or buflan:ti,ab,kw (Word variations have been
searched)
0
#33 diarfin or fonzylane:ti,ab,kw (Word variations have been
searched)
3
#34 irrodan:ti,ab,kw (Word variations have been searched) 0
#35 lofton or loftyl:ti,ab,kw (Word variations have been searched) 3
#36 #31 or #32 or #33 or #34 or #35 145
#37 #30 and #36 in Trials 83
Appendix 2. Authors’ 2007 Pubmed search terms for safety data
((“Pyrrolidines/adverse effects”[Mesh] OR “Pyrrolidines/toxicity”[Mesh]) OR “Pyrrolidines/poisoning”[Mesh])) AND (“bu-
flomedil”[Substance Name] OR Buflomedil[Text Word])
WH A T ’ S N E W
Last assessed as up-to-date: 8 January 2013.
Date Event Description
12 February 2013 New search has been performed Searches were rerun but no new studies were identified
for inclusion or exclusion
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(Continued)
12 February 2013 New citation required but conclusions have not
changed
Searches were rerun but no new studies were identified
for inclusion or exclusion. Minor copy edits made to
the text. One author stepped down from author team
H I S T O R Y
Protocol first published: Issue 1, 1998
Review first published: Issue 1, 2001
Date Event Description
28 April 2009 New search has been performed LIMBtrial added to excluded studies. Copy editsmade
to the text
9 May 2008 Amended Converted to new review format.
11 November 2007 New citation required and conclusions have changed Substantive amendment. Additional safety and effi-
cacy data added in the light of withdrawal of 300 mg
tablets in France. Safety considerations expanded
20 August 2007 New citation required but conclusions have not
changed
Citation order changed.
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